Patients and responders | Received dose escalation* | Primary non-responders*‡ | Secondary non-responders* § |
---|---|---|---|
NA, not applicable. | |||
*Patients who received dose escalations without meeting the criteria for lack of response or flare were not included. | |||
†Responders were defined as patients who achieved at least 20% improvement in the number of tender and swollen joints from baseline at 8 weeks after the last dose escalation. | |||
‡A primary non-responder was a patient who did not respond at week 22. | |||
§A secondary non-responder was a patient who responded at week 22 but later flared. | |||
Patients whose dose was escalated correctly | 100 | 53 | 47 |
Patients with one dose escalation | 59 | 23 | 36 |
Responders, No (%)† | 51 (86.4) | 21 (91.3) | 30 (83.3) |
Patients with two dose escalations | 21 | 13 | 8 |
Responders, No (%)† | 17 (81.0) | 11 (84.6) | 6 (75.0) |
Patients with three dose escalations | 13 | 10 | 3 |
Responders, No (%)† | 12 (92.3) | 9 (90.0) | 3 (100.0) |
Patients with four dose escalations | 7 | 7 | 0 |
Responders, No (%)† | 0 (0.0) | 0 (0.0) | NA |